Letters Comparing HPV vaccines

Changing face of HPV related cancer in the UK

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6675 (Published 18 October 2011) Cite this as: BMJ 2011;343:d6675
  1. Andrew G Schache, Wellcome Trust-FDSRCS research training fellow1,
  2. Richard Simcock, consultant clinical oncologist2,
  3. Duncan C Gilbert, consultant clinical oncologist2,
  4. Richard J Shaw, clinical senior lecturer in head and neck surgery1
  1. 1Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GN, UK
  2. 2Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK
  1. schache{at}liverpool.ac.uk

As the UK nears a decision on continuation of the national human papillomavirus (HPV) vaccination programme, Jit and colleagues’ economic evaluation of the available vaccines makes compelling reading.1

When developing arguments for cost effectiveness of the bivalent and quadrivalent vaccines, the analysis bears heavily on available data for cervical cancer, …

View Full Text

Log in

Log in through your institution


* For online subscription